NCT03546166View on ClinicalTrials.gov

Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

March 11, 2021

Study Completion Date

March 11, 2022

Conditions
Carcinoma
Interventions
DRUG

Picato 0.05% Topical Gel

apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.

Trial Locations (1)

06000

University Hospital of Nice, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT03546166 - Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma | Biotech Hunter | Biotech Hunter